OMNIBUS SETTLEMENT AGREEMENTSettlement Agreement • October 3rd, 2018 • Marina Biotech, Inc. • Pharmaceutical preparations • California
The undersigned, Marina Biotech, Inc., a Delaware corporation (the “Company”), on the one hand, and Vuong Trieu, PhD, an individual resident in California (“VT”), Autotelic Inc., a Delaware corporation (“Autotelic”), Autotelic LLC, a Delaware limited liability company (“Autotelic LLC”), Autotelic BIO (“Autotelic Bio”), Oncotelic, Inc., a Delaware corporation (“Oncotelic”), and LipoMedics, Inc., a Delaware corporation (“Lipomedics”; each of VT, Autotelic, Autotelic LLC, Oncotelic and LipoMedics a “Counterparty” and collectively the “Counterparties”; each of Autotelic, Autotelic LLC, Oncotelic and LipoMedics a “Corporate Counterparty” and collectively the “Corporate Counterparties”; and the Counterparties together with the Company, the “Parties”) on the other hand, have entered into this Omnibus Settlement Agreement (this “Agreement”) as of September 28, 2018.
